Notman Donald 4

What Happened Donald Notman, Chief Operating Officer of Ocular Therapeutix (OCUL), sold 11,446 shares of common stock on Feb 12, 2026. The weighted average sale price was $9.04 per share, producing gross proceeds of about $103,472. This was a sale (not a purchase) and was executed under an automatic sell-to-cover instruction to satisfy tax withholding on RSU vesting, not as a discretionary trade.

Key Details

• Transaction date: 2026-02-12. Weighted average price: $9.04; price range reported $8.9950–$9.0950 across multiple trades.
• Shares sold/disposed: 11,446; approximate proceeds: $103,472.
• Shares owned after transaction: Not specified in the provided filing excerpt. (See the full Form 4 for post-transaction holdings.)
• Footnotes: F1 — sale executed under a durable automatic sell-to-cover instruction adopted May 13, 2022 to satisfy tax withholding for RSUs that vested Feb 11, 2026; F2 — weighted average price with multiple trade prices; reporting person will provide breakdown on request.
• Filing timeliness: Transaction reported in a Form 4 filed Feb 17, 2026 for a Feb 12, 2026 transaction (filed after the typical two-business-day window), so the filing appears late.

Context This was a routine tax-withholding sell-to-cover following RSU vesting rather than a discretionary sale; such transactions typically reflect tax obligations rather than a change in insider sentiment. The reporting person states the sales were not discretionary and was executed automatically.